A rise in cancer incidence, upcoming new therapies, and development of promising new biomarkers as well as key pharmaceuticals setting foot in the Bone Metastasis sphere serves as major growth boosters for the Bone Metastasis Market surge in the coming years.
LAS VEGAS, Oct. 25, 2021 /PRNewswire/ -- DelveInsight's Bone Metastasis in Solid Tumors Market Insightsreport proffers a detailed comprehension of Bone Metastasis in Solid Tumors market size by treatment, epidemiology, emerging therapeutics, current and forecasted Bone Metastasis in Solid Tumors market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
The market size of Bone Metastasis in Solid Tumors in the United States markets was found to be USD 1,713.6 million in 2020.
DelveInsight estimates that the Bone Metastasis in Solid Tumors market size of the United States shall grow at a CAGR of 2.24% during the forecast period (2018–2030), owing to the launch of upcoming therapies.
Key pharmaceutical companies in the Bone Metastasis in Solid Tumors markets such as Exelixis, Actuate Therapeutics, and others
The Bone Metastasis in Solid Tumors pipeline therapies includes Cabozantinib, 9-ING-41, and others that are expected to launch in the coming years.
The Bone Metastasis in Solid Tumors market size is anticipated to grow at a significant rate due to an increase in upcoming novel treatment therapies, development of promising circulating and tissue biomarkers, and increasing awareness of Bone Metastasis in Solid Tumors.
The Bone Metastasis in Solid Tumors market hurdles may include a lack of an effective multidisciplinary approach to treatment as well as diagnostic challenges.
As per DelveInsight's analysis, Bone Metastasis in Solid Tumors market pipeline therapies is expected to create a positive shift in the 7MM market during the forecast period (2021-2030).
Bone is a recurrent site of metastatic disease in advanced cancer patients. Even though almost all cancers can spread to the bone, Bone Metastasis is most commonly observed in breast, lung and prostate cancer patients. One of the most common symptoms of Bone Metastasis is pain. Bone Metastasis is classified as osteolytic, osteoblastic, or mixed lesions.
DelveInsight's assessments showed that in the United States, the cases of Bone Metastasis among the metastatic subset were 121,603 in breast cancer, followed by 96,601 in lung cancer, 93,191 in prostate cancer, and 57,960 in other solid tumors in 2020.
Currently marketed treatment therapies in Bone Metastasis in the Solid Tumor include bone-targeting agents (BTA) like zoledronic acid, pamidronate disodium, and Xgeva (denosumab),bisphosphonates, and radiation therapy which are indicated to prevent skeletal-related events (SREs) in patients with Bone Metastasis.
Much anticipated emerging Bone Metastasis in the Solid Tumor treatment therapies include Cabozantinib by Exelixis, which is a potent, small-molecule inhibitor of tyrosine kinases involved in normal cellular function and pathologic processes, such as tumor growth, angiogenesis and metastasis. The drug is currently being evaluated in Phase II clinical trial to study its efficacy in combination with fulvestrant in patients (18 years and older) with metastatic hormone-receptor-positive breast cancer with involvement of the bone. Another breakthrough therapy is 9-ING-41 from Actuate Therapeutics is a first-in-class, intravenously administered, maleimide-based small molecule potent selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor with significant pre-clinical antitumor activity. The drug is currently in Phase I/II clinical trial (1801 study) to evaluate the drug as monotherapy and in combination with chemotherapy in patients with refractory hematologic malignancies or solid tumors.
Persistent rising cases of Bone Metastasis in Solid Tumors offer opportunities to companies to launch new therapies in the market. New explorative therapies for the treatment of Bone Metastasis in Solid Tumors are expected to boost the market in the forecast period. Also, other factors like the new development of promising circulating and tissue biomarkers as well as an emerging novel approach to assess the treatment response act as prominent Bone Metastasis in Solid Tumors market amplifiers.
The diagnostic challenge while assessing the Bone Metastasis in Solid Tumors as well as a lack of an effective multidisciplinary approach to treatment may act as market limiting factors. Unreported and undiagnosed Bone Metastasis in Solid Tumors cases and the absence of effective treatment are also some of the major obstructions in Bone Metastasis in Solid Tumors market.
However, DelveInsight estimates that the new entry of key pharmaceuticals associated with the novel effective therapies, R&D, and the discovery of novel biomarkers for diagnosis, shall propel the expansion and growth prospects of Bone Metastasis in the Solid Tumors market.
DelveInsight's, "Metastatic Bone Pain – Pipeline Insight, 2021," report covers the pipeline drug profiles, including clinical and non-clinical stage products, comprehensive insights about 10+ companies, and 10+ pipeline drugs in the Metastatic Bone Pain pipeline landscape including Qilu Pharmaceuticals Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Progenics Pharmaceuticals, Yong Shun Technology Development, Q.Biomed Inc., Shanghai JMT-Bio Inc, and few others.
DelveInsight's, "Irritable Bowel Syndrome (IBS) - Pipeline Insight, 2021," report covers the pipeline drug profiles, including clinical and non-clinical stage products, comprehensive insights about 24+ companies, and 24+ pipeline drugs in the Irritable Bowel Syndrome pipeline landscape including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Takeda, Biomica, Dong-A ST Co Ltd, Metacrine, MGC Pharma, Napo Pharmaceuticals, Nobilis Therapeutics, Novome Biotechnologies, RQ-00310941, Renexxion, Vitality Biopharma, Oxford Cannabinoid Technologies, and several others.
"Bone Metastasis Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Bone Metastasis market. A detailed picture of the Bone Metastasis pipeline landscape, disease overview, commercial assessment, clinical assessment, mechanism of action, clinical studies, and product development activities.
DelveInsight's 'Alagille Syndrome (ALGS) – Market Insights, Epidemiology, and Market Forecast—2030' report proffer detailed analysis of epidemiology, treatments, pipeline therapies, and key companies including Mirum Pharmaceuticals, Albireo, and many others.
DelveInsight's, "Metastatic Bone Pain – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Metastatic Bone Pain pipeline landscape and key companies involved like Qilu Pharmaceuticals Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Progenics Pharmaceuticals, Yong Shun Technology Development, Q.Biomed Inc., Shanghai JMT-Bio Inc, and several others.
DelveInsight's 'Bone Anchored Hearing Systems-Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Bone Anchored Hearing Systems, market drivers, market barriers, unmet medical needs, and key companies involved like Sonic Innovations, Inc, Sonova Holding AG, Starkey Hearing Technologies, William Demant Holding Bernafon AZ, Cochlear Ltd, GN ReSound, Natus Medical Incorporated, Oticon A/S, Siemens AG, and several others.
DelveInsight's 'Bone Densitometers - Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Bone Densitometers and the historical and forecasted Bone Densitometers market trends, market drivers, market barriers, and key companies involved like General Electric Company, Hologic, Inc, Swissray, Osteosys Co. Ltd, MedWrench, LLC, Schick Sirona, DMS Imaging, Echolight S.p.a, Aarna Systems and Wellness Pvt. Ltd, Tecnicare Healthcare Company, and others.
DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.